Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.67 |
| ▸ | FERMT2 | Q96AC1 | 1/20 | 0.51 |
| ▸ | NCF1 | P14598 | 1/20 | 0.50 |
| ▸ | HTR1A | P08908 | 2/20 | 0.49 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.49 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4870416 | 0.95 | LOXL2 (0.65) | LOXL2FERMT2NCF1HTR1AADRA1D | |
| SCHEMBL14157416 | 0.93 | LOXL2 (0.62) | LOXL2FERMT2NCF1HTR1AADRA1D | |
| SCHEMBL10752255 | 0.93 | LOXL2 (0.62) | LOXL2FERMT2NCF1HTR1AADRA1D | |
| SCHEMBL10757258 | 0.93 | LOXL2 (0.62) | LOXL2FERMT2NCF1HTR1AADRA1D | |
| SCHEMBL6223283 | 0.89 | LOXL2 (0.71) | LOXL2FERMT2NCF1HTR1AADRA1D | |
| Hydrochloric Acid SCHEMBL20592932 | 0.87 | LOXL2 (0.69) | LOXL2FERMT2NCF1HTR1AADRA1D | |
| SCHEMBL2333461 | 0.86 | LOXL2 (0.62) | LOXL2FERMT2NCF1HTR1AADRA1D | |
| SCHEMBL2331919 | 0.86 | LOXL2 (0.62) | LOXL2FERMT2NCF1HTR1AADRA1D | |
| SCHEMBL7599320 | 0.83 | LOXL2 (0.58) | LOXL2FERMT2NCF1HTR1AADRA1D | |
| SCHEMBL7358307 | 0.81 | LOXL2 (0.56) | LOXL2FERMT2NCF1HTR1AADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109415649-A | Composition of hydraulic fluid | 路博润公司 | 2019-03-01 | — | — | CN | disclosed |
| CN-108368358-A | improved water separation using quaternary amine additives | 路博润公司 | 2018-08-03 | — | — | CN | disclosed |
| US-9815863-B2 | Hydrogen bond forming fluoro ketolides for treating diseases | CEMPRA PHARMACEUTICALS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| CN-107207889-A | For making the polyester dispersants that ceramic tile is coloured using ink jet type ink and ink-jet printer | 路博润先进材料公司 | 2017-09-26 | — | — | CN | disclosed |
| CN-103649279-B | The stabilized mixture that contains friction improver | THE LUBRIZOL CORP. (US) | 2016-05-04 | — | — | CN | disclosed |
| EP-2613630-A1 | HYDROGEN BOND FORMING FLUORO KETOLIDES FOR TREATING DISEASES | Cempra Pharmaceuticals, Inc. (US) | 2013-07-17 | — | — | EP | disclosed |
| US-20130172280-A1 | HYDROGEN BOND FORMING FLUORO KETOLIDES FOR TREATING DISEASES | CEMPRA PHARMACEUTICALS, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-8299035-B2 | 10a-azalide compound having 4-membered ring structure | TAISHO PHARMACEUTUCAL CO., LTD. (JP) | 2012-10-30 | — | — | US | disclosed |
| US-8293715-B2 | 10a-Azalide compound crosslinked at 10a- and 12-positions | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-10-23 | — | — | US | disclosed |
| WO-2012034058-A1 | HYDROGEN BOND FORMING FLUORO KETOLIDES FOR TREATING DISEASES | CEMPRA PHARMACEUTICALS, INC. (US) | 2012-03-15 | — | — | WO | disclosed |
| EP-1568692-A1 | (pyridin-4-yl)alkyl-amides as TNF-alpha production inhibitors | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-08-31 | — | — | EP | disclosed |
| CN-1639181-A | Novel 15-membered cyclic azalide, novel 16-membered cyclic diazalide derivative, and process for producing these | MEIJI SEIKA KAISHA (JP) | 2005-07-13 | — | — | CN | disclosed |
| CN-1604774-A | Angiogenesis inhibitor | SANTEN PHARMACEUTICAL CO LTD (JP) | 2005-04-06 | — | — | CN | disclosed |
| CN-1590375-A | TNF-alpha prodn. inhibitors | SANTEN PHARMACEUTICAL CO LTD (JP) | 2005-03-09 | — | — | CN | disclosed |
| CN-1590374-A | TNF-alpha prodn. inhibitors | SANTEN PHARMACEUTICAL CO LTD (JP) | 2005-03-09 | — | — | CN | disclosed |
| US-20050014800-A1 | Angiogenesis inhibitor | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| EP-1479687-A1 | NOVEL 15-MEMBERED CYCLIC AZALIDE, NOVEL 16-MEMBERED CYCLIC DIAZALIDE DERIVATIVE, AND PROCESS FOR PRODUCING THESE | MEIJI SEIKA KAISHA LTD. (JP) | 2004-11-24 | — | — | EP | disclosed |
| CN-1432000-A | TNF-alpha production inhibitors | SANTEN PHARMACEUTICAL CO LTD (JP) | 2003-07-23 | — | — | CN | disclosed |
| EP-1302461-A1 | TNF-ALPHA PRODUCTION INHIBITORS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2003-04-16 | — | — | EP | disclosed |
| US-20030032623-A1 | Tnf-alpha production inhibitors | AYUMI PHARMACEUTICAL CORPORATION (JP) | 2003-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014800-A1 | Angiogenesis inhibitor | FLT4, KDR, FLT1 | LOXL2 2581/4885FERMT2 3035/4885NCF1 1212/4885 |
| US-20130172280-A1 | HYDROGEN BOND FORMING FLUORO KETOLIDES FOR TREATING DISEASES | Q6ZSR9, LSS, LCT | LOXL2 1901/4885FERMT2 1527/4885NCF1 2526/4885 |
| US-20030032623-A1 | Tnf-alpha production inhibitors | TNF, TNFRSF1A, TNFRSF9 | LOXL2 2802/4885FERMT2 2282/4885NCF1 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.